专业监测看板

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

药物 / 成分：Oxycodone、Acetaminophen、Ketamine、Ketorolac

登记的停止原因（原文）：Study initially suspended following an audit and need of amendment to address deficiencies. PI requested to terminate due to lack of support.

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

药物 / 成分：NX-13 250mg、NX-13 750mg、NX-13 Placebo

登记的停止原因（原文）：Sponsor Decision\_Not Safety Related

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

药物 / 成分：BE-101、BE-101、BE-101、BE-101

登记的停止原因（原文）：The study was terminated due to a strategic business decision and not due to safety concerns

Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure

药物 / 成分：Heparin、NaCl

登记的停止原因（原文）：Difficulty of inclusion

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

药物 / 成分：PDA-002、Placebo

登记的停止原因（原文）：The study was terminated early due to a business decision.

Impact of Male Smoking on the Couple's Infertility

药物 / 成分：smoking behavior、Sperm collection

登记的停止原因（原文）：recruitement difficulties

Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders

药物 / 成分：Variation of behaviors of Parkinson's disease

登记的停止原因（原文）：Zambon corparate has decided not to renew the production of the samples.

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

药物 / 成分：Poziotinib

登记的停止原因（原文）：Strategic business decision (unrelated to safety)

Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation

药物 / 成分：5 days of systemic corticotherapy (prednisone)、5 days of placebo

登记的停止原因（原文）：low enrollment at participating centers

COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction

药物 / 成分：Colchicine

登记的停止原因（原文）：Inclusion period completed

Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

药物 / 成分：MEMOPTIC、usual treatment of glaucoma

登记的停止原因（原文）：recruitement difficulties

Cannabidiol for Reducing Drinking in Alcohol Use Disorder

药物 / 成分：Cannabidiol oral oil、Placebo oral oil

登记的停止原因（原文）：Péremption des unités de traitement prévue début juin 2026. Compte tenu des délais de traitement, aucune administration ne sera plus possible après le 1 février 2026. Ces facteurs ne permettent plus de garantir la poursuite des inclusions.

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

药物 / 成分：ARO-ANG 3 Injection

登记的停止原因（原文）：Business decision, unrelated to safety concerns.

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

药物 / 成分：NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

登记的停止原因（原文）：The study was terminated due to initiation of a new clinical trial with an updated study design.

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

药物 / 成分：Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab

登记的停止原因（原文）：The study was closed due to accrual.

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

药物 / 成分：VVD-130850、Pembrolizumab

登记的停止原因（原文）：The study has ended

Pregabalin Versus Placebo as an Add on for Complex Regional Pain Syndrome (CPRS) of the Upper Limb Managed by Stellate Ganglion Block (The PREGA Study)

药物 / 成分：Pregabalin、Placebo

登记的停止原因（原文）：Unable to recruit patients

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

药物 / 成分：[18F]FES

A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT

药物 / 成分：Temferon

登记的停止原因（原文）：LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged.

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

药物 / 成分：efineptakin alfa、Atezolizumab

登记的停止原因（原文）：sponsor decision (not for safety)